Onkologie. 2023:17(4):230-232 | DOI: 10.36290/xon.2023.044

Treatment of BRAF V600E-mutated metastatic colorectal cancer

Jiří Tomášek
Masarykův onkologický ústav, Brno

Colorectal cancers can be divided into several subgroups according to their molecular characteristics. A small subgroup comprises cancers with a BRAF mutation. The negative prognostic significance of this mutation in metastatic colorectal cancer (mCRC) has long been known; in recent years, we have made use of the fact that it is also a strong predictor of the efficacy of combined targeted therapy with cetuximab + encorafenib. The present paper deals with the treatment of patients with mCRC and BRAF V600E mutation.

Keywords: colorectal cancer, BRAF mutation, cetuximab, encorafenib, immunotherapy.

Accepted: October 3, 2023; Published: October 5, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tomášek J. Treatment of BRAF V600E-mutated metastatic colorectal cancer. Onkologie. 2023;17(4):230-232. doi: 10.36290/xon.2023.044.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1): 10-32. Go to original source... Go to PubMed...
    2. Ciombor KK, Strickler JH, Bekaii-Saab TS, et al. BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. J Clin Oncol. 2022;40(24):2706-2715. doi: 10.1200/JCO.21.02541. Epub 2022 Jun 1. Go to original source... Go to PubMed...
    3. Sahin IH, Klostergaard J. BRAF Mutations as Actionable Targets: A Paradigm Shift in the Management of Colorectal Cancer and Novel Avenues. JCO Oncol Pract. 2021;17(12):723-730. doi: 10.1200/OP.21.00160. Epub 2021 Jun 2. Go to original source... Go to PubMed...
    4. Modrá kniha ČOS 29. aktualizace, 2023. Available from: www.linkos.cz.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.